Carpmaels & Ransford takes UPC initiative

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Carpmaels & Ransford takes UPC initiative

The UK patent and trade mark attorney firm Carpmaels & Ransford is adding a team of litigators in preparation for the launch of the Unified Patent Court

ian-kirby-1.jpg

The firm announced today that it has hired partners Ian Kirby (pictured) and Jonathan Day from Arnold & Porter's London office.

Kirby, a patent litigator, has already joined the firm. Day, a solicitor and trade mark attorney, joins on September 22.

Managing IP understands that a third solicitor, specialising in life sciences, is also expected to join the firm soon.

The move comes ahead of the launch of the EU Unitary Patent and Unified Patent Court, expected in 2016.

Hugh Goodfellow, the firm's head of life sciences, told Managing IP: "With the launch of the Unitary Patent and UPC, we believe these additions will enable us to offer clients a comprehensive IP service."

Historically, there has been a clear divide in the UK between firms of patent and trade mark attorneys and firms of solicitors, who often referred work to each other.

However, in recent years this has broken down as patent firms such as Marks & Clerk and HGF have set up associated litigation practices, and others such as D Young and EIP have added solicitors. Going in the other direction, some law firms such as Olswang have hired patent attorneys.

Carpmaels' initiative goes further than some other firms as it is understood that all the new members will have equal status to the existing partners, and be part of the same firm.

It comes as many European firms are evaluating how best to advise clients on the UPC, including whether they need to add expertise or new offices.

"As patent attorneys we are very experienced in opposition work, which we think will prepare us well for UPC proceedings. Adding solicitors gives us extra experience in for example evidence gathering and witness preparation, but most importantly of all, for the strategic insights which only come from years of experience conducting litigation across Europe," said Goodfellow.

He added that the new hires are part of a long-term strategy: "We expect that we will make further additions in the future as the UPC develops."

more from across site and SHARED ros bottom lb

More from across our site

Canadian law firms should avoid ‘tunnel vision’ as exclusive survey reveals client dissatisfaction with risk management advice and value-added services
In major recent developments, the CoA ruled on director liability for patent infringement, and Nokia targeted Paramount at the UPC and in Germany
Niri Shan, the newly appointed head of IP for UK, Ireland and the Middle East, explains why the firm’s international setup has brought UPC success, and addresses German partner departures
Vlad Stanese joins our ‘Five minutes with’ series to discuss potentially precedent-setting trademark and copyright cases and his love for aviation
Heath Hoglund, president of Via LA, discusses how it sets royalty rates and its plans to build on growth in China
Stobbs stands accused of interfering with the administration of justice after Brandsmiths’ client was subjected to an interim injunction for unjustified threats
The firm, known for its prosecution expertise, discusses its plans following the appointment of a UK-based patent litigation head and two new partners
Ed White at Clarivate provides an exclusive insight into the innovation power clusters reshaping Europe and the Middle East’s IP landscape, and why quality is the new currency of invention
In the first in a new podcast series celebrating the tenth anniversary of IP Inclusive, we look back at the network’s origins and discuss its mission
Rebecca Schwarz at Haynes Boone shares how her team secured victory for biopharma client RedHill in a licensing dispute involving a developmental cancer drug
Gift this article